Moreover, a PAR2 inhibitor markedly reactivated gefitinib to prevent tumor growth in PC-9-GR xenograft mice (Figure 5), confirming that PAR2 inhibition could overcome gefitinib resistance in vivo. Here, F2RL1 is linked to neoplasm.